News

Dr Murphy first joined Lilly in 1980 as a personnel representative in Basingstoke, UK, and was named to his current role in June 2005. During his 28-year career

The marketing authorization application (MAA) submission is based on positive results from a randomized, double-blind, placebo-controlled Phase III study of pazopanib in treatment-naïve and cytokine-pre-treated patients with advanced

Alnylam and Isis were the sole and equal investors in the financing. Regulus was established in September of 2007 by Alnylam and Isis to focus on the discovery,

Aerovance, a biopharmaceutical company, has received clearance from the FDA and the UK Medicines and Healthcare products Regulatory Agency to initiate its Phase IIb clinical trial, AeroTrial, of

This acquisition is reported to be part of Axis-Shield’s strategy to set up direct distribution in key countries such as Germany, which has the potential to become the

Mr Casdagli has been an active investor in life sciences since joining MVM in 2002. Before joining MVM, he worked at PricewaterhouseCoopers where he qualified as a chartered

According to the company, the shield successfully crossed all target lesions and was safely implanted in all 30 patients, with a technical success rate of 100%. No procedural

Michael Adams, president and CEO of AdvanSource Biomaterials, said: “We sincerely appreciate Eric’s contributions since he joined the company in October 2005 as a seasoned financial executive, including

The intranasal method was developed by William Frey II, senior director of HealthPartners Research Foundation’s Alzheimer’s Research Center, and his colleagues. According to Sanomune, the new method allows